Studies have demonstrated that PARP inhibitor efficacy in BRCA mutated ovarian and breast cancer, prostate cancer, pancreatic cancer and small cell lung carcinoma (SCLC)14. This evidence concerns the gene PARP1 and pancreatic neoplasm.